Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002773 · ClinicalTrials.gov registry record · Phase 2
Vaccine Therapy, Chemotherapy, and GM-CSF in Treating Patients With Advanced Pancreatic Cancer
A Phase 2 study, sponsored by St. Vincent Medical Center - Los Angeles.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00002773: Completed Phase 2 study, sponsored by St. Vincent Medical Center - Los Angeles.
NCT00002773 is a Phase 2 study that has completed, run by St. Vincent Medical Center - Los Angeles. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002773, a Phase 2 study, has completed, sponsored by St. Vincent Medical Center - Los Angeles.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Vaccines made from donated tumor cells treated with interferon alfa may make the body build an immune response to and kill pancreatic tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors may help a person's immune system recover from the side effects of chemotherapy. Combining these treatments may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining vaccine therapy using donated tumor cells treated with interferon alfa and radiation therapy and cyclophosphamide plus GM-CSF in treating patients with advanced pancreatic cancer.
Interventions
- DRUG cyclophosphamide
- BIOLOGICAL recombinant interferon alfa
- BIOLOGICAL sargramostim
- BIOLOGICAL allogeneic tumor cell vaccine
Trial Details
| Field | Value |
|---|---|
| Start Date | 1996-05 |
| Est. Completion | 2004-04 |
| Phase | Phase 2 |
What the finished NCT00002773 record still lists
NCT00002773 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 4 interventions - of which cyclophosphamide is the first listed.
NCT00002773 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002773 about?
NCT00002773 is a clinical study titled "Vaccine Therapy, Chemotherapy, and GM-CSF in Treating Patients With Advanced Pancreatic Cancer". RATIONALE: Vaccines made from donated tumor cells treated with interferon alfa may make the body build an immune response to and kill pancreatic tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors may he...
What is the current status of trial NCT00002773?
This trial is currently completed. It is a Phase 2 study. The study started on 1996-05. Estimated completion is 2004-04.
What interventions are being tested in trial NCT00002773?
The interventions under investigation include: cyclophosphamide (DRUG), recombinant interferon alfa (BIOLOGICAL), sargramostim (BIOLOGICAL), allogeneic tumor cell vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00002773?
This trial is sponsored by St. Vincent Medical Center - Los Angeles, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia